There was no difference in overall survival between patients with MDS/CMML and those with AML.
Response rates and overall survival were superior in the triplet group.
The disparity was driven by patients aged 18-29 years.
Most outcomes were similar for patients who received gilteritinib plus azacitidine and those who received azacitidine alone.
Most events occurred during treatment cycles 1 and 2.
GO plus cytarabine was no more effective than standard chemotherapy and appeared particularly detrimental for women.